Kimberly Scearce‐Levie

10.5k total citations · 1 hit paper
55 papers, 5.8k citations indexed

About

Kimberly Scearce‐Levie is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Physiology. According to data from OpenAlex, Kimberly Scearce‐Levie has authored 55 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Cellular and Molecular Neuroscience, 25 papers in Molecular Biology and 21 papers in Physiology. Recurrent topics in Kimberly Scearce‐Levie's work include Alzheimer's disease research and treatments (20 papers), Neuroscience and Neuropharmacology Research (17 papers) and Neurotransmitter Receptor Influence on Behavior (10 papers). Kimberly Scearce‐Levie is often cited by papers focused on Alzheimer's disease research and treatments (20 papers), Neuroscience and Neuropharmacology Research (17 papers) and Neurotransmitter Receptor Influence on Behavior (10 papers). Kimberly Scearce‐Levie collaborates with scholars based in United States, France and Singapore. Kimberly Scearce‐Levie's co-authors include Lennart Mucke, Jorge J. Palop, Hertzel C. Gerstein, Irene H. Cheng, Tiffany Wu, Gui-Qiu Yu, Fengrong Yan, Erik D. Roberson, René Hen and Nga Bien‐Ly and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Kimberly Scearce‐Levie

55 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model

2007 1.5k citations Erik D. Roberson, Kimberly Scearce‐Levie et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kimberly Scearce‐Levie United States	35	3.0k	2.4k	2.1k	974	896	55	5.8k
Christian Czech Switzerland	38	4.1k 1.4×	2.8k 1.2×	1.5k 0.7×	1.1k 1.1×	990 1.1×	115	6.2k
Yong Shen United States	28	2.8k 0.9×	2.2k 0.9×	1.5k 0.7×	706 0.7×	998 1.1×	91	5.6k
Haakon B. Nygaard United States	21	2.9k 1.0×	2.3k 1.0×	1.6k 0.8×	617 0.6×	1.0k 1.1×	57	4.7k
Kelly T. Dineley United States	37	2.4k 0.8×	2.7k 1.1×	2.0k 0.9×	1.2k 1.2×	953 1.1×	67	5.3k
Takeshi Kawarabayashi Japan	31	4.1k 1.4×	2.2k 0.9×	1.3k 0.6×	889 0.9×	1.0k 1.1×	129	5.7k
Jill Richardson United Kingdom	40	2.6k 0.9×	2.8k 1.1×	1.5k 0.7×	701 0.7×	1.5k 1.7×	119	6.8k
Oliver Wirths Germany	46	4.9k 1.7×	2.3k 1.0×	1.9k 0.9×	1.1k 1.2×	1.4k 1.6×	120	6.7k
Howard T.J. Mount Canada	30	2.6k 0.9×	1.9k 0.8×	1.7k 0.8×	809 0.8×	963 1.1×	61	5.0k
Agata Copani Italy	54	3.3k 1.1×	4.0k 1.7×	4.0k 1.9×	946 1.0×	1.4k 1.6×	117	8.6k
Christopher Janus United States	30	4.3k 1.4×	2.4k 1.0×	2.4k 1.1×	1.1k 1.1×	1.8k 2.0×	53	6.9k

Countries citing papers authored by Kimberly Scearce‐Levie

Since Specialization

Citations

This map shows the geographic impact of Kimberly Scearce‐Levie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kimberly Scearce‐Levie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kimberly Scearce‐Levie more than expected).

Fields of papers citing papers by Kimberly Scearce‐Levie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kimberly Scearce‐Levie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kimberly Scearce‐Levie. The network helps show where Kimberly Scearce‐Levie may publish in the future.

Co-authorship network of co-authors of Kimberly Scearce‐Levie

This figure shows the co-authorship network connecting the top 25 collaborators of Kimberly Scearce‐Levie. A scholar is included among the top collaborators of Kimberly Scearce‐Levie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kimberly Scearce‐Levie. Kimberly Scearce‐Levie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Scearce‐Levie, Kimberly, Pascal E. Sanchez, & Joseph W. Lewcock. (2020). Leveraging preclinical models for the development of Alzheimer disease therapeutics. Nature Reviews Drug Discovery. 19(7). 447–462. 76 indexed citations

Bhalla, Akhil, Ritesh Ravi, Meng Fang, et al.. (2020). Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients. International Journal of Molecular Sciences. 21(15). 5188–5188. 21 indexed citations

Grievink, Hendrika W., Jules A. A. C. Heuberger, Fen Huang, et al.. (2019). DNL104, a Centrally Penetrant RIPK1 Inhibitor, Inhibits RIP1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers. Clinical Pharmacology & Therapeutics. 107(2). 406–414. 56 indexed citations

Wong, Kit Hong, Rajkumar Noubade, Paolo Manzanillo, et al.. (2017). Mice deficient in NRROS show abnormal microglial development and neurological disorders. Nature Immunology. 18(6). 633–641. 48 indexed citations

Ertürk, Ali, Maj Hedehus, Sara L. Domínguez, et al.. (2016). Interfering with the Chronic Immune Response Rescues Chronic Degeneration After Traumatic Brain Injury. Journal of Neuroscience. 36(38). 9962–9975. 68 indexed citations

Lo, Shih‐Ching, Yuan Yuan Wang, Martin Weber, et al.. (2015). Caspase-3 Deficiency Results in Disrupted Synaptic Homeostasis and Impaired Attention Control. Journal of Neuroscience. 35(5). 2118–2132. 31 indexed citations

Weber, Martin, Tiffany Wu, Jesse E. Hanson, et al.. (2015). Cognitive Deficits, Changes in Synaptic Function, and Brain Pathology in a Mouse Model of Normal Aging. eNeuro. 2(5). ENEURO.0047–15.2015. 57 indexed citations

Kallop, Dara, William J. Meilandt, Alvin Gogineni, et al.. (2014). A Death Receptor 6-Amyloid Precursor Protein Pathway Regulates Synapse Density in the Mature CNS But Does Not Contribute to Alzheimer's Disease-Related Pathophysiology in Murine Models. Journal of Neuroscience. 34(19). 6425–6437. 36 indexed citations

Hanson, Jesse E., Martin Weber, William J. Meilandt, et al.. (2013). GluN2B Antagonism Affects Interneurons and Leads to Immediate and Persistent Changes in Synaptic Plasticity, Oscillations, and Behavior. Neuropsychopharmacology. 38(7). 1221–1233. 44 indexed citations

10.

Liu, Xingrong, Harvey Wong, Kimberly Scearce‐Levie, et al.. (2013). Mechanistic Pharmacokinetic-Pharmacodynamic Modeling of BACE1 Inhibition in Monkeys: Development of a Predictive Model for Amyloid Precursor Protein Processing. Drug Metabolism and Disposition. 41(7). 1319–1328. 17 indexed citations

11.

Shin, Young G., L. Lee Hamm, Michael H. Buonarati, et al.. (2013). Qualification and application of a liquid chromatography–tandem mass spectrometric method for the determination of human Aβ1-40 and Aβ1-42 peptides in transgenic mouse plasma using micro-elution solid phase extraction. Archives of Pharmacal Research. 37(5). 636–644. 5 indexed citations

12.

Pichon, Claire E. Le, Sara L. Domínguez, Hilda Solanoy, et al.. (2013). EGFR Inhibitor Erlotinib Delays Disease Progression but Does Not Extend Survival in the SOD1 Mouse Model of ALS. PLoS ONE. 8(4). e62342–e62342. 33 indexed citations

13.

Hanson, Jesse E., Hank La, Emile G. Plise, et al.. (2013). SAHA Enhances Synaptic Function and Plasticity In Vitro but Has Limited Brain Availability In Vivo and Does Not Impact Cognition. PLoS ONE. 8(7). e69964–e69964. 93 indexed citations

14.

Meilandt, William J., Moustapha Cissé, Kaitlyn Ho, et al.. (2009). Neprilysin Overexpression Inhibits Plaque Formation But Fails to Reduce Pathogenic Aβ Oligomers and Associated Cognitive Deficits in Human Amyloid Precursor Protein Transgenic Mice. Journal of Neuroscience. 29(7). 1977–1986. 119 indexed citations

15.

Scearce‐Levie, Kimberly, Erik D. Roberson, Hertzel C. Gerstein, et al.. (2007). Abnormal social behaviors in mice lacking Fgf17. Genes Brain & Behavior. 7(3). 344–354. 93 indexed citations

16.

Esposito, Luke, Jacob Raber, Fengrong Yan, et al.. (2006). Reduction in Mitochondrial Superoxide Dismutase Modulates Alzheimer's Disease-Like Pathology and Accelerates the Onset of Behavioral Changes in Human Amyloid Precursor Protein Transgenic Mice. Journal of Neuroscience. 26(19). 5167–5179. 215 indexed citations

17.

Chin, Jeannie, Jorge J. Palop, Jukka Puoliväli, et al.. (2005). Fyn Kinase Induces Synaptic and Cognitive Impairments in a Transgenic Mouse Model of Alzheimer's Disease. Journal of Neuroscience. 25(42). 9694–9703. 265 indexed citations

18.

Scearce‐Levie, Kimberly, Jue Chen, Eliot L. Gardner, & René Hen. (1999). 5‐HT Receptor Knockout Mice: Pharmacological Tools or Models of Psychiatric Disorders. Annals of the New York Academy of Sciences. 868(1). 701–715. 49 indexed citations

19.

Scearce‐Levie, Kimberly, et al.. (1999). Locomotor response to MDMA is attenuated in knockout mice lacking the 5-HT 1B receptor. Psychopharmacology. 141(2). 154–161. 75 indexed citations

20.

Rocha, Beatriz, Kimberly Scearce‐Levie, José J. Lucas, et al.. (1998). Increased vulnerability to cocaine in mice lacking the serotonin-1B receptor. Nature. 393(6681). 175–178. 239 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact